Nonsteroidal anti-inflammatory drug-induced gastropathy;Gastropatía por anti-inflamatorios no esteroideos

Revista de Investigacion Clinica

Volumn 49, Issue 3, 1997, Pages 241-254

  Márquez Murillo, Manlio Favio ^a   Suazo, Jorge ^a   Poo, Jorge Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cicloxygenase; Cytoprotection; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGE; AGED; ALGORITHM; ANIMAL; CHEMICALLY INDUCED DISORDER; CHILD; DRUG EFFECT; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PHYSIOLOGY; PREVALENCE; RAT; REVIEW; RISK FACTOR; STOMACH MUCOSA; STOMACH ULCER; VASCULARIZATION;

ADULT; AGE FACTORS; AGED; ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CHILD; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MIDDLE AGED; NEUTROPHILS; PREVALENCE; RATS; RISK FACTORS; STOMACH ULCER;

EID: 0042778968     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Roth SH, Bennet RE. NSAIDs, peptic ulcer, esophageal disease, and gastropathy. En: Famaey JP, Paulus HE (eds). Therapeutic applications of NSAIDs. Subpopulations and new formulation. New York:Dekker; 1992:279-98.
2. Katona-Salgo G. Inflamación y tratamiento antiinflamatorio. Un reto de todos los tiempos. Gac Med Mex 1989; 125:2137-9.
3. Kraus A, Ibañez G. Anti-inflamatorios no esteroideos. Una revisión práctica. Rev Invest Clin 1985; 37:153-64.
4. Semble EL, Wu WC. Anti-inflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum 1987; 16:271-86.
5. Faulkner G, Prichard P, Somerville K, Langman MJS. Aspirin and bleeding peptic ulcers in the elderly. Br Med J 1988; 297:1311-3.
6. Murry MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 32:436.
7. Mohamed AH, Salena BJ, Hunt RH. NSAID-induced gastroduodenal ulcers: exploring the silent dilemma. J Clin Gastroenterol 1994; 29 (Suppl VII): 34-8.
8. Bobadilla J, Villalobos JJ, Gómez A, Vargas T. Epidemiología de la úlcera péptica (UP) en el Instituto Nacional de la Nutrición Salvador Zubirán (INNSZ). Rev Gastroenterol Mex 1993; 58 (Suppl): 299-300.
9. Téllez A, Flores S, Carrillo LA. Curvas de sangrado de tubo digestivo en el Centro Médico del Noreste, IMSS. Rev Gastroenterol Mex 1990; 54 (Suppl): 366.
10. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989; 32:926-32.
11. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983; 74:820-8.
12. Committee on Safety Medicines. Nonsteroidal antiinflamatory drugs and serious gastrointestinal adverse reactions. Br Med J 1986; 292:614.
13. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal anti-inflamatory drug therapy. Gastroenterology 1989; 96:675-81.
14. Fries JF, Williams CA, Block DNA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91:213-22.
15. Beard K, Walter AM, Perera DR, Jick H. Nonsteroidal antiinflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Inter Med 1987; 147:1621-3.
16. Carson JL, Strom BL, Soper KA, Est SI, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987; 147:85-8.
17. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109:359-63.
18. Laporte JR, Carné X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337:86-9.
19. Savage RL, Moller PW, Bellantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum 1993; 36:85-90.
20. Arteaga D, Valenzuela F. Papel de las prostaglandinas en la inflamación, en la función renal y en la preservación de la mucosa gástrica y consecuencias del bloqueo de su síntesis. Rev Mex Reumat 1988; 3:97-102.
21. Earnest DL. NSAID-induced gastric injury: its pathogenesis and management. Semin Arthritis Rheum 1990; 19 (Suppl 2): 6-10.
22. Kimmey MB. NSAID, ulcers, and prostaglandins. J Rheumatol 1992; 19 (Suppl. 36): 68-73.
23. Simon LS. Actions and toxic effects of the nonsteroidal anti-inflammatory drugs. Curr Opinion Rheumatol 1994; 6:238-51.
24. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 1985; 89:1162-88.
25. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109:285-301.
26. Ligumsky M, Sestieri M, Karmeli F, Zimmerman J, Okon E, Rachmilewitz D. Rectal administration of nonsteroidal anti-inflammatory drugs. Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. Gastroenterology 1990; 88:1245-9.
27. Redfern JS, Lee E, Feldman M. Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage. Gastroenterology 1987; 92:969-77.
28. McCarthy DM. Pathogenic mechanisms of gastroduodenal injury: nonsteroidal anti-inflammatory drugs. Curr Opinion Gastroenterol 1991; 7:876-80.
29. Ivey KJ Paone BD, Krause WJ. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci 1980; 25:97-9.
30. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994; 39:362-5.
31. Wallace JL, Keenan CM, Granger N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990; 259: G462-7.
32. Wallace JL, Arfors KI, Mcknigh GW. A monoclonal antibody against the CD 18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991; 100:878-83.
33. Levi S, Goodlad RA, Lee CY, Stamp G, Walport MJ, Wrhight NA, et al. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet 1990; 336:840-3.
34. Soll AH, Weinstein WM, Kurata J, McCarthy DM. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307-19.
35. Martínez Osuna P. La inflamación y los radicales libres de oxígeno. Rev Mex Reumat 1990; 5: 16-22.
36. Hicks JJ, Guzmán-Grenfell MA. Los radicales libres en el daño tisular y en la inflamación. Rev Mex Reumat 1994; 6: 225-30.
37. Vaananen P, Meedings JB, Wallace JL. Role of reactive oxygen metabolites in experimental NSAID gastropathy (abstract). Gastroenterology 1991; 100: 1846.
38. Konturek SK, Konturek PC. Role of nitric oxide in the digestive system. Digestion 1995; 561:1-13.
39. Dehesa M, Dooley CP, Cohen H, Fitzgibbons P, Pérez G, Blaser M. Prevalencia elevada de Campylobacter pylori (CP) en una población hispana asintomática. Rev Gastroenterol Mex 1989;54(Supp 1):281.
40. Bernal R, Martinez G, Hernandez A. Prevalencia de Helicobacter pylori (HP) en enfermedad ácido péptica, neoplasias gástricas y en sujetos sanos; estudio comparativo. Rev Gastroenterol Mex 1993; 58 (Suppl): 297-8.
41. Sánchez O, Guerrero F, Bosques F, Nidershauser A, Barbosa A, Martinez L, et al. Prevalencia de Helicobacter pylori y su relación con patología gastroduodenal. Experiencia en un hospital universitario. Rev Gastroenterol Mex 1993; 58 (Suppl): 301.
42. Caselli M, Pazzi P, La Corte R. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989; 44:101-4.
43. Taha AS, Lee FD, Sturrock RD, Nakshabendi I, Gemmell CG, Russell RI, et al. Chemical gastritis and Helicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAID)-correlation with peptic ulceration. Gastroenterology 1991; 100:A171.
44. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1991; 87:1398-402.
45. Graham DY, Lidsky MD, Cox AM, Evans DJ, Evans DG, Alpert L, et al. Long-term nonsteroidal anti-inflammatory drugs use and Helicobacter pylori infection. Gastroenterology 1991; 100:1653.
46. Laine L. Helicobacter pylori, gastric ulcer, and agents noxious to the gastric mucosa. Gastroenterol Clin North Am 1993; 22:117-25.
47. Jones STM, Clague RB, Eldridge J. Jones DM. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to nonsteroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. Br J Rheumatol 1991; 30:16-20.
48. Buchanan WW. Implications of NSAID therapy in elderly patients. J Rheumatol 1990;17 (Suppl.20): 29-32.
49. Moore JG, Bjorkman DJ, Mitchell MD, Avots-Avotins A. Age does not influence acute aspirin-induced gastric mucosal damage. Gastroenterology 1991; 100:1626-9.
50. Langman MJS. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 1988; 84 (Suppl 2A): 15-8.
51. Llewellyn JG, Pritchard MH. Influence of age and disease state in nonsteroidal anti-inflammatory drug-associated gastric bleeding. J Rheumatol 1988; 15:691-4.
52. Skander MP, Ryan FP. Nonsteroidal anti-inflammatory drugs and pain-free peptic ulceration in the elderly. Br Med J 1988; 297:833-4.
53. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J 1988; 297:1017-21.
54. Douthwaite AH, Lintott GAM. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938; 2:1222.
55. Halvorsen L, Dotevall G, Sevelius H. Comparative effects of aspirin and naproxen on gastric mucosa. Scand J Rheumatol 1976; 2 (Suppl.2):43-7.
56. Rahbek I. Gastroscopic evaluation of the effect of a new antirheumatic compound, ketoprofen (18, 583 R.P.) on the human gastric mucosa. A double-blind cross-over trial against acetylsalicylic acid. Scand J Rhematol 1976;5 (Suppl. 14): 63-72.
57. Lehtola J, Sipponen P.A. Gastroscopic and histological double-blind study of the effects of diclofenac sodium and naproxen on the human gastric mucosa. Scand J Rheumatol 1977; 6: 97-102.
58. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potencial for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993; 95 (Suppl 2A): 40-4.
59. Cryer B, Gottesdiener K, Gertz B, Hsieh P, Dallob A, Feldman M. Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans. Am J Gastroenterol 1996; 91:1907.
60. Dammann HG, Burkhardt F, Walter ThA. Selective COX-2 inhibition: its relevance for NSAID-gastrointestinal toxicity. Am J Gastroenterol 1996; 91:1910.
61. Brooks PM, Day RO. Nonsteroidal anti-inflammatory durgs differences and similarities. N Eng J Med 1991; 324:1716-25.
62. Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 1990; 99:1616-21.
63. Willkens RF. The selection of a nonsteroidal anti-inflammatory drug. Is there a difference? J Rheumatol 1992; 19 (suppl. 36): 9-12.
64. Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987;83 (Suppl 4B): 25-30.
65. Dvornik D. Mecanismo teórico para la seguridad gastrointestinal del etodolac: respeto selectivo de las prostaglandinas citoprotectoras. Rev Mex Reumat 1989; 4 (Suppl 5): 3-7.
66. Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, et al. Incidence of gastric lesions in patients with rheumatic diseases on chronic aspirin therapy. Ann Intern Med 1979; 91: 517-20.
67. Lanza LF, Rover GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303: 136.
68. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? J Clin Gastroenterol 1993; 17:238-43.
69. Graham DY, Smith LJ, Dobbs MS. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983; 28:1-6.
70. Caruso I, Bianchi-Porro GB. Gastroscopic evaluation of anti-inflammatory agents. Br Med J 1980;280: 75-8.
71. Robinson MG, Griffen JW, Bowers J, Kogan FJ, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by non-steroidal anti-inflammatory drugs. Dig Dis Sci 1989; 34: 424-8.
72. Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320(2):69-75.
73. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32.
74. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114: 735-40.
75. Larkai EN, Smith LJ, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1897; 92: 1153-8.
76. Somerville K, Faulkner G, Langman M. Nonsteroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1: 462-4.
77. Meddings JB, Sutherland LB, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993; 104: 1619-26.
78. McCarthy DM. NSAID-Induced gastrointestinal damage. A critical review of prophylaxis and therapy, J Clin Gastroenterol 1990; 12 (Suppl 2): S13-20.
79. O'Laughlin JC, Silvoso GK, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. Dig Dis Sci 1982; 27:976-80.
80. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory drug-induced gastroduodenal ulceration. N Eng J Med 1992;327:1575-80.
81. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind placebo-controlled trial. Lancet 1988; 11: 1277-80.
82. Simon B, Leucht U, Amon I, Brandau J, Muller P. Nizatidin in therapie und prophylaxe NSAR-induzierter gastroduodenaler ulzera beit rheumapatienten. Z Gastroenterol 1993; 31: 395-400.
83. Jiménez E, Bosch F, Galmes JL, Banos JE. Meta-analysis of efficacy of zinc acesamate in peptic ulcer. Digestion 1992; 5:18-26.
84. Rodríguez de la Serna A, Diaz-Rubio M, Spanish Study Group on NSAID Induced Gastroenteropathy Prevention. Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal anti-inflammatory drug induced gastroenteropathy. J Rheumatol 1994; 21:927-33.
85. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in non-steroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987; 147:1798-801.
86. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized controlled trial. Ann Intern Med 1991; 115:195-200.
87. Lanza F, Peace K, Gustitus L, Rack MF, Dickson B. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and doudenal ulceration. Am J Gastroenterol 1988; 83:143-6.
88. Caldwell JR, Roth SH, Wu WC Semble EL, Castell DO, Heller MD et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987; 83:74-82.
89. Berkowitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 1987; 147:2137-9.
90. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking anti-inflammatory drugs. Arch Intern Med 1993; 153:2449-54.
91. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nosteroidal anti-inflammatory drug-induced gatric and duodenal ulcers. A comparison of three regimens. Ann Intern Med 1995; 123:344-50.
92. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with reuhmatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
93. Downie WW. Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. Drugs 1993; 45 (Suppl 1):1-6.
94. Morgan MW, Detsky AS. It is unclear whether misoprostol is cost-effective in preventing SAID gastropathy. ACP J Club 1995; 122:53. Comment by Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994;154: 2020-5.
95. Morgan MW, Detsky AS. It is unclear whether misoprostol is cost-effective in preventing SAID gastropathy. ACP J Club 1995; 122:53. Comment by Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994;154: 2020-5.